JPMorgan Chase & Co. Lowers Stock Holdings in Indivior PLC (NASDAQ:INDV)

JPMorgan Chase & Co. decreased its position in shares of Indivior PLC (NASDAQ:INDV - Free Report) by 68.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 441,745 shares of the company's stock after selling 953,120 shares during the period. JPMorgan Chase & Co. owned approximately 0.32% of Indivior worth $4,307,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in Indivior by 7.7% during the third quarter. Geode Capital Management LLC now owns 132,239 shares of the company's stock valued at $1,289,000 after purchasing an additional 9,500 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new stake in Indivior during the third quarter valued at about $294,000. XTX Topco Ltd raised its position in Indivior by 763.4% during the third quarter. XTX Topco Ltd now owns 133,194 shares of the company's stock valued at $1,299,000 after purchasing an additional 117,767 shares in the last quarter. Krensavage Asset Management LLC purchased a new stake in Indivior during the third quarter valued at about $6,843,000. Finally, Jane Street Group LLC purchased a new stake in Indivior during the third quarter valued at about $180,000. Hedge funds and other institutional investors own 60.33% of the company's stock.

Indivior Trading Down 0.1 %

Shares of NASDAQ:INDV traded down $0.01 on Friday, reaching $11.65. 1,060,388 shares of the company traded hands, compared to its average volume of 974,047. The business's 50-day simple moving average is $11.46 and its 200 day simple moving average is $11.10. Indivior PLC has a 52 week low of $7.33 and a 52 week high of $23.22. The stock has a market capitalization of $1.61 billion, a P/E ratio of -291.18 and a beta of 0.74.

Indivior (NASDAQ:INDV - Get Free Report) last announced its quarterly earnings data on Thursday, October 24th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. The firm had revenue of $307.00 million for the quarter, compared to analysts' expectations of $302.25 million. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. Sell-side analysts expect that Indivior PLC will post 1.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Piper Sandler restated an "overweight" rating and set a $16.00 price target (up previously from $15.00) on shares of Indivior in a research report on Friday, October 25th. Craig Hallum reduced their price objective on Indivior from $20.00 to $16.00 and set a "buy" rating on the stock in a research note on Friday, October 11th.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.